NICE clears front-line NHS use for Pfizers lung cancer drug Vizimpro

Pharmaphorum | July 05, 2019

Pfizer has stolen a march on rival AstraZeneca in the first-line non-small cell lung cancer category, after NICE backed the use of its EGFR inhibitor Vizimpro for NHS use. The once-daily pill will now be routinely available for adults with locally advanced or metastatic non-small cell lung cancer (NSCLC), who have tested positive for the epidermal growth factor receptor (EGFR) mutation. Earlier, NICE rejected the drug on the grounds that it wasn’t a cost-effective use of NHS resources. AZ has not been so lucky, with the cost-effectiveness agency turning down its EGFR inhibitor Tagrisso (osimertinib) for the same indication, although the company has said it intends to appeal the decision. Pfizer has offered a discount on Vizimpro (dacomitinib), which was approved by the EMA in April and in the US last September. Its list price in the UK is £2,703 for a 30-day pack of capsules, but the agreed reduction is confidential. In a statement, NICE said Pfizer’s “responsible pricing” had allowed its appraisal committee to reconsider its initial decision. Both Vizimpro and Tagrisso were turned down by the agency in April after an initial assessment, with the committee deciding neither drug offered enough extra benefit to patients when compared with existing treatments to be value for money. “Our committee acknowledged that dacomitinib had the potential to extend life for people with this type of lung cancer more than existing treatments currently available on the NHS,” said Meindert Boysen, director of the Centre for Health Technology Evaluation at NICE.

Spotlight

Following a live debate with UK Independence Party Leader and anti-EU activist Nigel Farage, Aaron D Barzey of ADB Medical, was invited onto ITV's Good Morning Britain show to discuss the potential impact of the UK leaving the European Union to the pharmaceutical industry.


Other News
BUSINESS INSIGHTS

Model N and Pfizer Innovate Drug Price Transparency Reporting

Model N, Inc. | August 04, 2022

Model N, Inc. the leader in revenue optimization and compliance, announced the launch of Transparency Talks, a new, three-part education series for pharmaceutical companies that tackles the topic of price transparency regulations for prescription drugs. Transparency Talks will bring together leaders from Model N, Pfizer and Global Pricing Innovations (GPI) to explore state drug pricing laws and regulations, as well as facilitate a discussion on trends, best practices and innovative approaches that help pharmaceutical companies meet regulatory compliance goals. First-Ever SaaS Solution for State Price Transparency Mandates Model N has pioneered a technology-driven approach to state price transparency regulations. Its new State Price Transparency Management (SPTM) solution for the Model N Revenue Cloud is the first-ever SaaS solution built specifically to assist pharmaceutical and biotech companies in operationalizing the complete, end-to-end process for meeting State Price Transparency mandates. “Life sciences companies must find an effective way to prepare and respond to fast-moving changes in state price transparency regulations, and we are excited to deliver innovative solutions to help them avoid costly mistakes. t’s been an honor to partner with Pfizer on State Price Transparency Management, creating an innovative solution that helps navigate the fluid state drug price reporting landscape.” Kyle Forcier, Senior Director of Life Sciences Product Marketing at Model N Pfizer and GPI on SPTM The SPTM solution was developed with the collaboration of Pfizer, the world’s largest pharmaceutical company. “Our collaboration with Model N has delivered a tool that helps us better manage complex state reporting requirements,” said Laura Topal, Senior Director, Strategic Pricing, Pfizer. “We’re proud of what we have achieved together, and we’re excited about sharing our learnings with the larger pharma community.” Rachel Jao, Head of Commercial Strategy from GPI, a market leader in innovative solutions for biopharma and market access, will also join Transparency Talks to share the latest in industry best practices. “More than 20 states have drug pricing transparency laws on the books today, and there can be severe financial consequences for non-compliance,” Jao said. “Transparency Talks from Model N is a valuable way for pharma business leaders to learn more about the current regulatory environment and to explore solutions that will help them address this significant challenge.” About Model N Model N is the leader in revenue optimization and compliance for pharmaceutical, medtech and high-tech innovators. Our intelligent platform powers your digital transformation with integrated technology, data, analytics, and expert services that deliver deep insight and control. Our integrated cloud solution is proven to automate pricing, incentive and contract decisions to scale business profitably and grow revenue. Model N is trusted across more than 120 countries by the world’s leading pharmaceutical, medical technology, semiconductor, and high-tech companies, including Johnson & Johnson, AstraZeneca, Stryker, Seagate Technology, Broadcom, and Microchip Technology.

Read More

BUSINESS INSIGHTS

Spotlight Therapeutics Appoints Visionary Global Pharma Drug Developer Antoine Yver, M.D., M.Sc. as First Independent Board Member

Spotlight Therapeutics | July 18, 2022

Spotlight Therapeutics, Inc. a biotechnology company applying new insights to develop cell-targeted in vivo CRISPR gene editing biologics, announced the appointment of Antoine Yver, M.D., M.Sc. to the Spotlight Board of Directors. Trained as an oncologist and immunologist, Dr. Yver’s extensive industry experience and perceptive acumen will be extremely valuable as Spotlight continues to strengthen its highly differentiated TAGE platform and advance lead therapeutic candidates towards the clinic. “We are thrilled to welcome Antoine to Spotlight’s Board of Directors. Few people in our industry enjoy such a remarkable track record of successful drug development, exercising extreme rigor in following the science to deliver practice-changing medicines that serve patients with significant unmet medical needs.” Mary Haak-Frendscho, Ph.D., President and Chief Executive Officer of Spotlight As Executive Vice President and Global Head of Oncology R&D at Daiichi Sankyo, Dr. Yver played a key role in the development of the new breakthrough cancer biologic, Enhertu®, that is redefining breast cancer treatment and promises to set a new standard of care, as well as other Daiichi Sankyo DXd ADCs. From 2009 to 2016, Dr. Yver held executive leadership positions at AstraZeneca, including SVP & Global Head of Oncology Development. Under his leadership, Tagrisso® and Lynparza® were successfully developed and commercialized for patients. Prior to joining AstraZeneca, Dr. Yver held roles at Merck, Johnson & Johnson, Aventis and Rhone-Poulenc Rorer. Dr. Yver is Executive Vice President and Chairman of Development at Centessa Pharmaceuticals plc and currently serves as an Independent Director of the Board of Directors at Sanofi. “I am delighted to join the Spotlight Board and support the mission to unlock the full potential of gene editing and enable effective single administration therapeutics for patients,” said Dr. Yver. “Spotlight’s biologics-based delivery approach has the potential to forge a new generation of cell-targeted in vivo CRISPR gene editing medicines across multiple therapeutic areas.” “Antoine’s deep insights and vast global pharma experience will help propel Spotlight to becoming a clinical stage company,” said Craig Gordon, M.D., Spotlight board member, Founder, CEO, and CIO of GordonMD™ Global Investments. “We look forward to working together to impact the strategic decisions of the company that will ultimately provide benefit to patients.” About Spotlight Therapeutics Established in mid-2018, Spotlight Therapeutics is a privately held biotechnology company advancing a pipeline of cell-targeted in vivo CRISPR gene editing therapies. Spotlight's proprietary technology platform TAGE is a new class of biologics, CRISPR effectors engineered for direct delivery in vivo, to achieve cell-selective therapeutic genome editing. Spotlight's pipeline is advancing its modular programmable CRISPR effectors towards clinical studies in immuno-oncology, ophthalmic diseases and hemoglobinopathies.

Read More

BUSINESS INSIGHTS

UCB Showcases Strength of the Expanding Dermatology Portfolio at the 31st EADV Congress

UCB, Inc. | September 02, 2022

UCB, a global biopharmaceutical company, today announced that it will present 20 abstracts across its dermatology portfolio at the 31st European Academy of Dermatology and Venereology (EADV) Congress in Milan, Italy, September 7-10. The abstracts, accepted for poster presentation, underscore UCB's commitment to delivering innovative solutions that aim to address the unmet needs of people living with dermatological diseases. "We are proud to present new data from our expanding dermatology portfolio at the 31st EADV Congress. At UCB, our ambition is to transform the lives of people living with severe diseases such as psoriasis and psoriatic arthritis, and the strength of scientific data at this year's congress reaffirms our long-standing commitment to raising standards of care," said Emmanuel Caeymaex, Executive Vice President, Immunology Solutions and Head of U.S., UCB. Key data to be presented on UCB's investigational product bimekizumab include new results from the BE BRIGHT open-label extension study evaluating maintenance of response with bimekizumab through three years in patients with moderate to severe plaque psoriasis who responded at week 16 during Phase 3 clinical studies. New analysis of pooled safety data from up to three years of treatment with bimekizumab in the treatment of moderate to severe plaque psoriasis across Phase 2 and 3 clinical trials will also be presented. Bimekizumab is an investigational product; its efficacy and safety have not been established for any indication in the U.S. and it is not approved by the U.S. Food and Drug Administration (FDA). For CIMZIA® (certolizumab pegol), data to be presented include three-year data from three Phase 3 trials evaluating the association of patient-reported outcomes (Dermatology Life Quality Index, DLQI 0/1) with relative skin clearance improvements (Psoriasis Area and Severity Index, PASI) in subgroups of adult patients with moderate to severe plaque psoriasis. About UCB UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 8,600 people in approximately 40 countries, the company generated revenue of €5.8 billion in 2021. UCB is listed on Euronext Brussels (symbol: UCB).

Read More

PHARMACY MARKET

iA Commemorates 50 Years of Innovation with Launch of New Pharmacy Solutions at NACDS Total Store Expo

iA | August 26, 2022

iA, a leading provider of pharmacy fulfillment and automation solutions, is celebrating 50 years of innovation at NACDS Total Store Expo. With a commitment to its heritage, iA’s mission has never wavered from streamlining operational processes through advancing technology. Today, iA continues to drive pharmacy industry innovations. From safe and accurate filling of prescriptions through the use of modern robotics, to production control software enhanced by warehouse management technology, iA’s solutions are powered by its intelligent software platform, NEXiA. NEXiA is the foundation of iA’s automated fulfillment solutions, spanning retail and central fulfillment. “Our NEXiA platform allows our hardware and third-party solutions to talk, streamlining the end-to-end fulfillment process. This allows pharmacies of varying sizes the benefits of flexible on-time delivery, can aid in lowering cost-to-fill and can provide the time needed to spend with patients.” NEXiA’s continuous evolution allows for comprehensive capabilities that drive omnichannel pharmacy fulfillment — from prescription acceptance to quality verification and delivery. Marvin Richardson, RPh, Chief Executive Officer of iA As the industry has evolved, iA has maintained its focus and commitment to pharmacy innovation by launching iA SmartStart, a solution designed to enable customers to realize the benefits of central fill faster. “We’ve listened to our customers and recognized their need to quickly reduce in-store workload and focus on value-added services. SmartStart allows customers to recognize these benefits in 120 days from contracting,” said Alecia Lashier, Chief Automation Officer of iA. Leveraging NEXiA, SmartStart can accelerate growth to higher levels of automation. The addition of hardware, such as iA SmartPod — a fully contained dispensing system capable of labeling, filling, imaging and capping — allows the transition from SmartStart to a fully automated production facility. SmartPod’s flexible and modular design scales with expanding prescription volume and mix, enabling pharmacies to expand as their business grows. As iA looks to the next 50 years of innovation with a commitment to industry partnership, iA is introducing shared central fulfillment solutions. By leveraging NEXiA, including its cloud modules, iA’s shared central fulfillment solutions allow multiple pharmacy organizations to coexist within a single facility. “As the industry continues to evolve, this model brings together forward-thinking partners of various sizes seeking common goals to reduce cost and improve patient care. Regardless of where you are in your pharmacy fulfillment journey, iA will partner with you to maximize your investment,” said Tom Utech, PharmD, Group President, Product and Software of iA. “We are committed to serving pharmacists and their patients. Total Store Expo is the perfect opportunity to take a moment to celebrate all that iA has provided to the pharmacy community thus far and look forward to another successful 50 years of innovation,” added Richardson. iA executives are available to connect at Booth 1505 at Total Store Expo. About iA iA is a leading-edge provider of software-enabled pharmacy fulfillment solutions. With over 25 years in pharmacy fulfillment, iA has invented and developed a suite of software-driven pharmacy automation solutions. From NEXiA software to automated modular hardware and sophisticated counting and collation devices, iA pharmacy automation solutions and technology empower pharmacists. iA can run the prescription fulfillment process from end to end, helping pharmacies manage fulfillment and inventory to help lower costs, improve efficiency and provide comprehensive Rx tracking and real-time support. For high-volume centralized fulfillment or pharmacy operations — iA can help customers transform their pharmacy.

Read More

Spotlight

Following a live debate with UK Independence Party Leader and anti-EU activist Nigel Farage, Aaron D Barzey of ADB Medical, was invited onto ITV's Good Morning Britain show to discuss the potential impact of the UK leaving the European Union to the pharmaceutical industry.

Resources